Alterity Therapeutics Limited
ATHENASDAQHealthcare● Active
$3.92
+$0.02(+0.46%)
Market Cap$35534263
P/E Ratio—
52W High$7
52W Low$2.66
Alterity Therapeutics Limited (ATHE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATHE · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 25, 2026EPS Actual
-$0.38
Est. -$0.23 · -65.9%
Revenue
$0.00B
Est. $0.00B · -39.6%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 25, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
ATHE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 28, 2026 | -$0.25 | — | — | — | $0.00B | — |
| ▼ Q1 FY2026 | Feb 25, 2026 | -$0.23 | -$0.38 | -65.9% | $0.00B | $0.00B | -39.6% |
| ▲ Q3 FY2025 | Aug 28, 2025 | -$0.43 | -$0.40 | +7.2% | $0.00B | $0.01B | -24.1% |
| ◌ Q3 FY2025 | Aug 4, 2025 | — | — | — | — | — | — |
| ▲ Q1 FY2025 | Feb 28, 2025 | -$0.53 | -$0.00 | +99.9% | $0.00B | $0.00B | -65.1% |
| — Q1 FY2025 | Feb 3, 2025 | — | -$0.00 | — | $0.00B | — | — |
| ▲ Q3 FY2024 | Aug 29, 2024 | -$0.05 | -$0.00 | +96.2% | $0.00B | $0.00B | +123.0% |
| — Q2 FY2024 | Apr 11, 2024 | — | -$0.00 | — | $0.00B | — | — |
Q3 FY2026
Aug 28, 2026
EPS Actual
—
EPS Est.
-$0.25
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$0.38
EPS Est.
-$0.23
EPS Surpr.
-65.9%
Revenue
$0.00B
Q3 FY2025
Aug 28, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.43
EPS Surpr.
+7.2%
Revenue
$0.00B
Q3 FY2025
Aug 4, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Feb 28, 2025Beat
EPS Actual
-$0.00
EPS Est.
-$0.53
EPS Surpr.
+99.9%
Revenue
$0.00B
Q1 FY2025
Feb 3, 2025
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 29, 2024Beat
EPS Actual
-$0.00
EPS Est.
-$0.05
EPS Surpr.
+96.2%
Revenue
$0.00B
Q2 FY2024
Apr 11, 2024
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.70 | $-0.70 | $-0.70 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2024 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2024 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 25, 2026 | -65.9% | $3.33 | $3.43 | +3.00% |
| ▲ Q3 FY2025 | Aug 28, 2025 | +7.2% | $5.00 | $5.02 | +0.40% |
| ▲ Q1 FY2025 | Feb 28, 2025 | +99.9% | $3.87 | $3.78 | -2.33% |
| — Q1 FY2025 | Feb 3, 2025 | — | $4.80 | $4.99 | +3.96% |
| ▲ Q3 FY2024 | Aug 29, 2024 | +96.2% | $1.41 | $1.51 | +7.09% |
| — Q2 FY2024 | Apr 11, 2024 | — | $2.19 | $2.63 | +20.09% |
| ▲ Q1 FY2024 | Feb 28, 2024 | +97.5% | $1.90 | $1.91 | +0.53% |
| — Q1 FY2024 | Jan 30, 2024 | — | $2.10 | $2.27 | +8.10% |
Q1 FY2026+3.00%
Report Date
Feb 25, 2026
EPS Beat/Miss
-65.9%
Price Before
$3.33
Price After
$3.43
Q3 FY2025+0.40%
Report Date
Aug 28, 2025
EPS Beat/Miss
+7.2%
Price Before
$5.00
Price After
$5.02
Q1 FY2025-2.33%
Report Date
Feb 28, 2025
EPS Beat/Miss
+99.9%
Price Before
$3.87
Price After
$3.78
Q1 FY2025+3.96%
Report Date
Feb 3, 2025
EPS Beat/Miss
—
Price Before
$4.80
Price After
$4.99
Q3 FY2024+7.09%
Report Date
Aug 29, 2024
EPS Beat/Miss
+96.2%
Price Before
$1.41
Price After
$1.51
Q2 FY2024+20.09%
Report Date
Apr 11, 2024
EPS Beat/Miss
—
Price Before
$2.19
Price After
$2.63
Q1 FY2024+0.53%
Report Date
Feb 28, 2024
EPS Beat/Miss
+97.5%
Price Before
$1.90
Price After
$1.91
Q1 FY2024+8.10%
Report Date
Jan 30, 2024
EPS Beat/Miss
—
Price Before
$2.10
Price After
$2.27
Avg Beat Reaction+1.42%
Avg Miss Reaction+3.00%
Beat Rate4 / 8 quarters
Largest Move+20.09% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATHE ends December
Alterity Therapeutics Limited (ATHE) most recently reported earnings on February 25, 2026 for Q1 FY2026, posting EPS of $-0.38 — missing the analyst consensus of $-0.23 by -65.9%. The next ATHE earnings date is expected around September 1, 2026.
Each quarter, investors track ATHE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATHE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATHE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATHE earnings · 5 questionsAlterity Therapeutics Limited's next earnings report is expected around September 1, 2026. ATHE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATHE historically reports after market close (AMC).
ATHE earnings datewhen is ATHE earningsATHE next earnings datewhen does ATHE report earningsATHE earnings calendar
▸ Source: FMP · Alterity Therapeutics Limited SEC filings · US GAAP · Alterity Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026